JCV Antibody Program in patients with Relapsing MS and who are Receiving or Considering Treatment with Tysabri
Multiple Sclerosis (MS) patients taking Tysabri have an increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), a type of brain infection. The JC virus is associated with PML. This study measures the antibodies to the JC virus in blood samples taken from MS patients who are taking Tysabri to investigate the possibility of a correlation between the presence or absence of the JC virus antibodies and a higher or lower risk of getting PML.
Neuroscience - Multiple Sclerosis,
Peiqing Qian, MD
Cherry Hill Campus
Potential study patients must have
*relapsing Multiple Sclerosis
*must be receiving Tysabri
*or considering treatment with Tysabri
Patients participating in any other Tysabri clinical trial or study sponsored by Biogen, Idec, or Elan.
Name: Lauren Lennox and Becky Wood